行情

MNOV

MNOV

美第奇新星生物技术
NASDAQ

实时行情|Nasdaq Last Sale

4.990
-0.640
-11.37%
休市 16:00 02/21 EST
开盘
5.14
昨收
5.63
最高
5.43
最低
4.940
成交量
17.02万
成交额
--
52周最高
13.37
52周最低
4.940
市值
2.19亿
市盈率(TTM)
-16.5781
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MNOV价格均价为20.00,最高价位22.00,最低价为18.00。

EPS

MNOV 新闻

更多
  • The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
  • Benzinga · 2天前
  • MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan
  • GlobeNewswire · 5天前
  • The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
  • Benzinga · 02/07 13:27
  • The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
  • Benzinga · 01/31 14:09

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

MNOV 简况

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
展开

微牛提供MediciNova, Inc.(NASDAQ-MNOV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MNOV股票新闻,以帮助您做出投资决策。